The Effect of Omega-3 FA on Hypertriglyceridemia in Patients With T2DM(OCEAN)

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 309 participants.

Also called NCT03120299

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 309 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT03120299
Other papers using this trial's data
  • Impact of omega-3 fatty acids on hypertriglyceridemia, lipidomics, and gut microbiome in patients with type 2 diabetes Med (New York, N.Y.), 2025-01-10 DOI, PubMed 39163858

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
China (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT03120299. Randomized; quadruple masking; primary purpose treatment. Start 2017-05-01 (actual); primary completion 2021-03-01 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
The Effect of Omega-3 FA on Hypertriglyceridemia in Patients With T2DM(OCEAN)
Condition
Type 2 Diabetes Mellitus
Condition
Hypertriglyceridemia
Intervention (Drug)
Omega-3 fatty acid
Intervention (Drug)
Placebos
Lead sponsor
Shanghai Jiao Tong University School of Medicine (class: other)

Record details

Record id
cardio:ct-nct03120299
Content hash
8c1b04f09b2591f5ee9d93fd4a2723bf89e0d68720e03dee0baeb36e38f9475a